In 51 menopausal women with HIV and genitourinary syndrome of menopause, 12 weeks of open-label vaginal estradiol reduced vaginal symptom index more than no treatment (P<.0001), though both groups improved; microbiome and mucosal immune mediators did not change.
RCTn = 51
Murphy et al. Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV